Omeros: YARTEMLEA Is Off To A Blistering Start (NASDAQ:OMER)
Omeros Corporation has received a Buy rating due to YARTEMLEA's unexpectedly strong launch, generating $28.5 million in net sales and positive operating cash flow in its first full quarter. The drug's adoption is rapidly increasing across transplant centers, with high formulary approval rates and …